The Role of Glycemic Variability in Cardiovascular Disorders

Abstract

Diabetes mellitus (DM) is one of the most common and costly disorders that affect humans around the world. Recently, clinicians and scientists have focused their studies on the effects of glycemic variability (GV), which is especially associated with cardiovascular diseases. In healthy subjects, glycemia is a very stable parameter, while in poorly controlled DM patients, it oscillates greatly throughout the day and between days. Clinically, GV could be measured by different parameters, but there are no guidelines on standardized assessment. Nonetheless, DM patients with high GV experience worse cardiovascular disease outcomes. In vitro and in vivo studies showed that high GV causes several detrimental effects, such as increased oxidative stress, inflammation, and apoptosis linked to endothelial dysfunction. However, the evidence that treating GV is beneficial is still scanty. Clinical trials aiming to improve the diagnostic and prognostic accuracy of GV measurements correlated with cardiovascular outcomes are needed. The present review aims to evaluate the clinical link between high GV and cardiovascular diseases, taking into account the underlined biological mechanisms. A clear view of this challenge may be useful to standardize the clinical evaluation and to better identify treatments and strategies to counteract this DM aspect.

Glycated hemoglobin as a surrogate for evaluating the effectiveness of drugs in diabetes mellitus trials: a systematic review and trial-level meta-analysis

“…This is because there is some evidence suggesting that factors other than glucose concentration affect glycation of hemoglobin, thus questioning the validity of HbA1c as a surrogate for mean blood glucose (46). However, more research is still required to determine the ability of different glycemic parameters to predict changes in final outcomes in DM (47).…”

EF24 exerts cytotoxicity against NSCLC via inducing ROS accumulation

“…5 A and B, EF24 causes a dose-dependent increase in DCF-responsive ROS in NSCLC cells. It has been reported that ROS overproduction can activate mitochondrial morphological changes, which possesses an irreplaceable position in the regulation of cell death and apoptosis [ 23 ]. Herein, after treatment with EF24, the mitochondrial morphology in A549 cells was also determined by fluorescence immunocytochemistry.…”

Long-term glycemic variability and risk of stroke in patients with diabetes: a meta-analysis

“…The possible mechanisms underlying the association between glycemic fluctuation and stroke may be multifactorial. Pathophysiologically, glucose fluctuation, particularly the short-term glycemic fluctuation has been associated with the severity of systematic atherosclerosis, possibly via the inducing oxidative stress, inflammatory cytokines, and endothelial damage [ 27 , 28 ]. Consistently, a recent cross-sectional study showed that glucose fluctuation is significantly associated with severe siphon stenosis of internal carotid artery in T2DM patients, suggesting that glucose fluctuation might be a risk factor for intracranial artery stenosis and ischemic stroke [ 29 ].…”